The year 2023 marks 60 years since the first pacemaker was implanted in Poland. The number of implantable cardiac electrotherapy devices (CIEDs), including pacemakers, cardioverter-defibrillators, and resynchronization therapy systems, has been systematically increasing in the subsequent decades. It is estimated that nearly 500,000 Poles have an implanted cardiac electrotherapy device, making optimal diagnostic imaging with the use of magnetic resonance imaging (MRI) a clinically and epidemiologically important issue.
View Article and Find Full Text PDFPurpose: Results of the low-dose radiation therapy (LDRT) in patients with pneumonia due to COVID-19 has been presented.
Methods: Fifteen patients received a single-fraction radiation dose of 1 Gy to the bilateral lungs due to pre-ARDS pneumonia in the course of COVID-19. Follow-up was performed on days 1, 3, 5, 7, 14 after LDRT.
Purpose: Daily image-guided radiation therapy significantly reduces setup errors, but it does not minimize intrafractional target mobility; respiratory-induced target motion is one of the reasons for this. Therefore, the main aim of this study was to evaluate the impact of respiratory-induced prostate motion on the clinical target volume (CTV) margins.
Methods: The analysis comprised 50 videos stored in digital format and recorded in a group of 50 patients during image-guided radiation therapy for prostate cancer.
Introduction: The use of fiducial markers in patients undergoing teleradiotherapy increases the precision of treatment under the condition that the marker does not displace itself during this treatment. In order to determine the accuracy of the verification method used to establish patient position, it is necessary to establish the possible marker migration range during planning and treatment with radiation therapy.
Material And Method: An analysis of the migration of GoldAnchorTM fiducial markers implanted in the prostate conducted on a group of 29 patients treated with image-guided radiation therapy at the Radiotherapy Department of the Cancer Centre and Institute of Oncology in Gliwice.